GNRH2 and breast carcinoma: GnRH-I, GnRH-I-agonists, GnRH-I-antagonists, and GnRH-II-agonists did not increase apoptosis in EC, ovarian, or breast cancer cell lines, but rather protected cells from programmed cell death [58,59].